20 Jul Kiji Therapeutics
Miguel Forte, M.D., Ph.D., President and CEO
Oct. 11 | 1:45pm | Rentschler ATMP Ballroom
Kiji Therapeutics has been incorporated in France and Spain in 2023 and is developing engineered off-the-shelf allogeneic cell therapies for multiple indications. The first asset, MSC engineered with CXCR4/IL10, targets autoimmune diseases and is planned to be in the clinic by the second half of 2024. Kiji’s platform will use different cell sources, donor and iPSC derived together with multiple gene engineering approaches to achieve improved therapeutic benefits.